Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Enacts Bill to Amend Infectious Disease Act
Japan’s Diet on December 2 enacted a comprehensive bill to amend health-related laws including the Infectious Disease Act, with a majority vote given at an Upper House plenary meeting. The proposed amendment of the Infectious Disease Act would allow the…
To read the full story
Related Article
- Upper House Health Committee OKs Bill to Amend Infectious Disease Act
November 25, 2022
- Bill to Amend Infectious Disease Act Clears Lower House
November 9, 2022
- Lower House Health Committee OKs Revised Bill to Amend Infectious Disease Act
November 7, 2022
- Bill to Amend Infectious Disease Act and Other Laws Enter Diet Deliberations
October 26, 2022
- Japan Cabinet OKs Bill to Amend Infectious Disease Act, Other Laws
October 11, 2022
- Japan Convenes Diet Session; Bill Submission Planned to Amend Infectious Disease Act, Medical Care Act
October 4, 2022
- LDP OKs Draft Bill to Amend Infectious Disease Act to Enable Requests for Vaccine Production Boost in Emergencies
September 21, 2022
REGULATORY
- MHLW Lifts Olanzapine Diabetes Contraindication for Antiemetic Use
August 26, 2026
- PMDA Flags Severe Gastritis, Esophagitis with Checkpoint Inhibitors
August 26, 2026
- Japan Grants Sakigake Tag to NS-035, MSA-01
August 26, 2026
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
August 25, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…